BioNTech SE
BNTX
#872
Rank
$28.276 B
Marketcap
Germany
Country
$112.56
Share price
21.29%
Change (1 day)
2.54%
Change (1 year)
Categories
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast…
Key Metrics
Trailing P/E
—
Forward P/E
-19.55
EPS (TTM)
$-7.74
Forward EPS
$-5.63
Price / Book
1.18
EV / EBITDA
-8.4x
Beta
1.29
Dividend Yield
—
Return on Equity
-9.30%
Return on Assets
-5.41%
Debt / Equity
1.78
Current Ratio
7.85
Gross Margin
76.62%
Operating Margin
-806.63%
Net Profit Margin
-63.64%
Free Cash Flow
$-249,562,496
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
-15.08%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$3.269B
Latest Net Income$-1,293,963,481
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare BioNTech SE with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
BNTX
No recent news available. Set FINNHUB_API_KEY to enable news.
